A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors. (MasterKey-01)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04209465 |
|
Recruitment Status :
Terminated
(The development of BDTX-189 was discontinued by the sponsor.)
First Posted : December 24, 2019
Last Update Posted : October 14, 2022
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
This is a clinical study with an orally administered drug, BDTX-189 in participants with advanced solid tumors that have select mutations or alterations in human epidermal growth factor receptor 2 (HER2/ErbB2) genes or epidermal growth factor receptor (EGFR/ErbB1). The main goals of this study are to:
- Find the recommended dose of BDTX-189 that can be given safely to participants
- Learn more about the side effects of BDTX-189
- Learn what the body does to BDTX-189 after it has been taken (pharmacokinetics or PK)
- Determine the antitumor activity of BDTX-189 in participants with select allosteric ErbB gene mutations
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Solid Tumor | Drug: BDTX-189 | Phase 1 Phase 2 |
BDTX-189 is an irreversible, small molecular inhibitor that is highly selective versus wild-type EGFR and potent for cancer driver mutations of the ErbB family, including extracellular, transmembrane, and kinase domain allosteric mutations of HER2, as well as EGFR and HER2 exon 20 insertion mutations. These allosteric ErbB mutations are found in 1 - 2 % of most solid tumors and enriched in some cancers with a prevalence of about 2 - 7% such as in non-small cell lung cancer, breast cancer, colorectal cancer, bladder cancer, and endometrial cancer. Currently approved HER2 and EGFR directed therapies are not active against the spectrum of allosteric mutations at relevant and tolerated exposure levels.
This Phase 1/2 multi-center, open-label trial is a first-in-human study that will evaluate BDTX-189 orally administered daily as a single agent in patients with solid tumors harboring select mutations or alterations. The Phase 1 portion is a dose escalation primarily designed to assess the safety and tolerability of BDTX-189 and to determine a recommended Phase 2 dose (RP2D). Phase 1 will focus on patients with a solid tumor with alterations such as:
- Allosteric HER2 or HER3 mutation(s)
- EGFR or HER2 exon 20 insertion mutation(s)
- HER2 amplified or overexpressing tumors
- EGFR exon 19 deletion or L858R mutation
Following selection of the RP2D, a Phase 2 portion will be initiated to further evaluate the clinical activity of BDTX-189. Phase 2 will focus on patients with a solid tumor harboring an:
- Allosteric HER2 mutation (including but not limited to S310F/Y, R678Q, L755S/P, V777L, V842I)
- EGFR or HER2 exon 20 insertion mutation
Eligible mutations must be determined by a validated next-generation sequencing (NGS) test routinely used by each institution and performed in a CLIA-certified or equivalent laboratory.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 91 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Sequential Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | MasterKey-01: A Phase 1/2, Open-label, Two-part, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics & Antitumor Activity of BDTX-189, an Inhibitor of Allosteric ErbB Mutations, in Patients w/ Advanced Solid Malignancies |
| Actual Study Start Date : | December 19, 2019 |
| Actual Primary Completion Date : | September 2, 2022 |
| Actual Study Completion Date : | September 16, 2022 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Phase 1 - Dose escalation
In Part A, cohorts of patients with select HER2, HER3, or EGFR alterations will receive increasing doses of BDTX-189. It is expected that up to approximately 70 patients will be enrolled in this dose escalation arm. If an alternative schedule is explored, up to 24 additional patients may be enrolled.
|
Drug: BDTX-189
Participants will receive a daily, oral dose of BDTX-189 as part of a 3 week cycle. |
|
Experimental: Phase 2 - Dose expansion
In Part B, patients with a solid tumor harboring specific allosteric HER2 mutations or an HER2 or EGFR exon 20 insertion mutation will receive the recommended Phase 2 dose of BDTX-189. It is expected that approximately 100 participants will be enrolled in this phase 2 portion.
|
Drug: BDTX-189
Participants will receive a daily, oral dose of BDTX-189 as part of a 3 week cycle. |
- Incidence of dose limiting toxicities as a determinant of the Recommended Phase 2 Dose (RP2D) [ Time Frame: After the first dose of treatment for up to 21 days. ]Certain toxicities will be considered dose-limiting unless clearly attributable to an extraneous cause, such as underlying disease.
- Phase 2: Objective response rate as a measure of antitumor activity [ Time Frame: Assessed until disease progression or death for up to 12 months ]Objective response rate is defined as the proportion of participants who achieve a confirmed complete response (CR; disappearance of all target and non-target lesions) or partial response (PR; at least a 30% decrease from baseline in the sum of diameters of target lesions) per RECIST version 1.1.
- Phase 1 and Phase 2: Incidence of treatment-emergent adverse events as a measure of safety and tolerability of BDTX-189 [ Time Frame: From Cycle 1 Day 1 (each cycle is 21 days) until 30 days post last dose ]Adverse events will be assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.
- Phase 1 and Phase 2: Plasma concentration of BDTX-189 as a measure of pharmacokinetics [ Time Frame: Multiple time points during Cycles 1-4 (each cycle is 21 days) ]Blood samples will be taken to measure the plasma concentrations of BDTX-189 in both a fed and fasted state.
- Phase 1: Objective response rate as a preliminary measure of antitumor activity [ Time Frame: Assessed until disease progression or death for up to 12 months ]Objective response is defined as the proportion of participants who achieved a complete response (CR; disappearance of all target and non-target lesions) or partial response (PR; at least a 30% decrease from baseline in the sum of diameters of target lesions) per RECIST version 1.1.
- Phase 1 and Phase 2: Duration of response as a measure of antitumor activity [ Time Frame: Assessed until disease progression or death for up to 12 months ]Duration of response is the time from first documentation of a response to first evidence of progressive disease per RECIST version 1.1 or death. A response is defined as either a complete response (CR; disappearance of all target lesions and non-target lesions) or partial response (PR; at least a 30% decrease in the sum of diameters of target lesions). Progressive disease is defined by a target lesion increase of 20% and at least 5mm from smallest on-study lesion sum, the appearance of new lesions, or unequivocal progression of non-target lesions.
- Phase 1 and Phase 2: Disease control rate as a measure of antitumor activity [ Time Frame: Assessed until disease progression or death for up to 12 months ]Disease control rate is defined as the proportion of participants achieving: a complete response (CR; disappearance of all target and non-target lesions), partial response (PR; at least a 30% decrease in the sum of diameters of target lesions), or stable disease (SD; neither sufficient shrinkage to qualify for a PR nor sufficient increase in lesions) per RECIST version 1.1.
- Phase 1 and Phase 2: Progression-free survival as a measure of antitumor activity [ Time Frame: Assessed until disease progression or death for up to 12 months ]Progression-free survival is the time from first study dose until disease progression (PD; target lesion increase of 20% and at least 5mm from smallest on-study lesion sum, the appearance of new lesions, or unequivocal progression of non-target lesions) per RECIST v1.1.
- Phase 2: Overall survival as a measure of clinical activity [ Time Frame: Assessed every 12 weeks after treatment discontinuation for up to 1 year ]Overall survival is the time from first study dose until death from any cause or study discontinuation.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Main Inclusion Criteria:
- Histologically- or cytologically-confirmed locally advanced or metastatic solid tumor with documented recurrence or disease progression from standard anticancer therapy in the advanced/metastatic setting
- No standard therapy available or standard therapy is considered unsuitable or intolerable according to the Investigator and consultation with the Medical Monitor
Phase 1 Only:
-
Solid tumor patients with alterations that may be associated with antitumor activity based on preclinical data for BDTX-189 such as:
- Allosteric HER2 or HER3 mutation(s)
- EGFR or HER2 exon 20 insertion mutation(s)
- HER2 amplified or overexpressing tumors
- EGFR exon 19 deletion or L858R mutation
Phase 2 Only:
-
Patients with a solid tumor harboring an:
- Allosteric HER2 mutation (including but not limited to S310F/Y, R678Q, L755S/P, V777L, V842I)
- EGFR or HER2 exon 20 insertion mutation
Eligible mutations must be determined by a validated next-generation sequencing (NGS) test routinely used by each institution and performed in a CLIA-certified or equivalent laboratory.
- Adequate archival tumor tissue or willing to undergo pretreatment biopsy
- Measurable disease according to RECIST version 1.1
Main Exclusion Criteria:
-
Clinical laboratory values meeting the following criteria within 4 weeks (28 days) prior to baseline:
- Serum creatinine ≥1.5 × upper limit of normal (ULN) or calculated creatinine clearance ≤60 mL/min using Cockcroft-Gault equation
- Total bilirubin ≥1.5 × ULN or ≥3.0 × ULN in the presence of documented Gilbert's syndrome
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥2.5 × ULN, or AST or ALT ≥5.0 × ULN in the presence of liver metastases
-
Hematologic function:
- Absolute neutrophil count (ANC) ≤1000 cells/μL
- Hemoglobin ≤8.5 g/dL or 5.28 mmol/L
- Platelet count ≤75,000/μL
-
Significant cardiovascular disease, including:
- Cardiac failure New York Heart Association Class III or IV, or left ventricular ejection fraction (LVEF) <50% or below the lower limit of the Institution's normal range
- Myocardial infarction, severe or unstable angina within 6 months prior to baseline
- Significant thrombotic or embolic events within 3 months prior to baseline
- History or presence of any uncontrolled cardiovascular disease
- Personal or family history of long QT syndrome
-
ECG findings meeting any of the following criteria:
- Evidence of second- or third-degree atrioventricular block
- Clinically significant arrhythmia (as determined by the Investigator)
- QTcF interval of >470 msec
- Leptomeningeal or untreated and/or symptomatic CNS malignancies (primary or metastatic)
- Women who are pregnant or breast-feeding
- Taking or unable to discontinue proton pump inhibitors within 1 week prior to baseline
- Known concurrent KRAS mutation
- Known tumor-harboring resistance mutations including EGFR T790M or C797S mutations or HER2 C805S mutation
Phase 2 Only:
- Prior documented treatment response to approved or investigational HER2 or EGFR tyrosine kinase inhibitor therapies
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04209465
Show 38 study locations
| Responsible Party: | Black Diamond Therapeutics, Inc. |
| ClinicalTrials.gov Identifier: | NCT04209465 |
| Other Study ID Numbers: |
BDTX-189-01 |
| First Posted: | December 24, 2019 Key Record Dates |
| Last Update Posted: | October 14, 2022 |
| Last Verified: | October 2022 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
|
solid tumor HER2 mutation exon 20 insertion mutation HER2 positive Genes, HER2 Genes, erbb2 HER2 amplification HER2 overexpression genes, exon 20 insertion |
lung cancer non-small cell lung cancer breast cancer colon cancer colorectal cancer bladder cancer endometrial cancer gastric cancer biliary tract cancer |